97
Participants
Start Date
April 30, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Dovitinib
Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Fulvestrant
Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
Dovitinib Placebo
Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Novartis Investigative Site, Surquillo
Novartis Investigative Site, Taichung
Novartis Investigative Site, Vienna
Novartis Investigative Site, Budapest
Novartis Investigative Site, Budapest
Novartis Investigative Site, Parktown
Novartis Investigative Site, Wilrijk
Novartis Investigative Site, Leuven
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Port Elizabeth
Novartis Investigative Site, Cape Town
Novartis Investigative Site, Rio Negro
Novartis Investigative Site, Taipei
ProHealth Care, Lake Success
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Troy
Virginia Cancer Specialists, PC Dept.ofFairfax SC, Fairfax
Novartis Investigative Site, Sondrio
Novartis Investigative Site, Besançon
Duke University Medical Center Duke (SC), Durham
Novartis Investigative Site, Madrid
Cancer Centers of the Carolinas Dept. of CC of the Carolinas, Greenville
Novartis Investigative Site, Bordeaux
H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC, Tampa
Novartis Investigative Site, Parma
Novartis Investigative Site, Saint-Herblain Cédex
Novartis Investigative Site, Toledo
Novartis Investigative Site, Valencia
Indiana University Health Goshen Center for Cancer SC, Goshen
Novartis Investigative Site, Lille
Novartis Investigative Site, Macerata
Nebraska Methodist Hospital Estabrook Cancer Center, Omaha
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville
Novartis Investigative Site, Thonon-les-Bains
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio
Novartis Investigative Site, Niaosong Township
Ironwood Cancer and Research Centers SC, Chandler
Cedars Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles
Novartis Investigative Site, Villejuif
Wenatchee Valley Medical Center Wenatchee Valley, Wenatchee
Medical Oncology Associates, PS, Spokane
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Ryazan
City of Hope National Medical Center COH 3, Duarte
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Ctr. SC-1, La Jolla
Oncology Specialists, SC Lutheran General Advanced Care, Park Ridge
Saint Barnabas Medical Center CancerCenter of Saint Barnabas, Livingston
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Córdoba
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Salvador
Novartis Investigative Site, Londrina
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São José do Rio Preto
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Győr
Novartis Investigative Site, Budapest
Novartis Investigative Site, Szeged
Novartis Investigative Site, Szolnok
Novartis Investigative Site, Maastricht
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Poznan
Novartis Investigative Site, Rzeszów
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY